Why the study?
What are the survival outcomes and predictors of benefit for dialysis in patients with primary systemic amyloidosis?
What are the survival outcomes and predictors of benefit for dialysis in patients with primary systemic amyloidosis?
In patients with primary systemic amyloidosis requiring dialysis, median survival is poor (<1 year), but those without cardiac involvement on echocardiogram may derive long-term benefit.
Dialysis in amyloidosis warrants echo evaluation before initiation; leaves open whether normal findings identify long-term beneficiaries.
Eighteen percent of patients with primary amyloidosis undergo dialysis. The 24-hour urinary protein loss and creatinine values are helpful in predicting which patients eventually will require dialysis. The median survival for patients starting dialysis is less than 1 year. Patients whose two-dimensional echocardiograms are normal are most likely to derive long-term benefit from dialysis.
No takes yet. Share an insight, caveat, or question.
Morie A. Gertz (1992) studied this question.